Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Other Accumulated Expenses (2016 - 2025)

Voyager Therapeutics' Other Accumulated Expenses history spans 11 years, with the latest figure at $549000.0 for Q4 2025.

  • For Q4 2025, Other Accumulated Expenses fell 54.29% year-over-year to $549000.0; the TTM value through Dec 2025 reached $549000.0, down 54.29%, while the annual FY2025 figure was $549000.0, 54.29% down from the prior year.
  • Other Accumulated Expenses for Q4 2025 was $549000.0 at Voyager Therapeutics, down from $1.2 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $7.0 million in Q3 2024 and bottomed at $549000.0 in Q4 2025.
  • The 5-year median for Other Accumulated Expenses is $3.2 million (2023), against an average of $4.0 million.
  • The largest annual shift saw Other Accumulated Expenses surged 6543.04% in 2021 before it tumbled 62.47% in 2024.
  • A 5-year view of Other Accumulated Expenses shows it stood at $5.6 million in 2021, then tumbled by 49.17% to $2.8 million in 2022, then grew by 12.99% to $3.2 million in 2023, then crashed by 62.47% to $1.2 million in 2024, then tumbled by 54.29% to $549000.0 in 2025.
  • Per Business Quant, the three most recent readings for VYGR's Other Accumulated Expenses are $549000.0 (Q4 2025), $1.2 million (Q4 2024), and $7.0 million (Q3 2024).